Alpha Family Trust lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,345 shares of the company’s stock after selling 140 shares during the quarter. Johnson & Johnson accounts for 0.7% of Alpha Family Trust’s holdings, making the stock its 24th largest holding. Alpha Family Trust’s holdings in Johnson & Johnson were worth $768,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $35,000. Retirement Financial Solutions LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $40,000. TD Capital Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC grew its stake in Johnson & Johnson by 112.8% during the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on JNJ shares. Credit Suisse Group boosted their target price on Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. UBS Group assumed coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Piper Sandler lowered their price objective on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.
Johnson & Johnson Stock Down 0.1 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.67 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.99%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is 94.56%.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets CloserÂ
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
